Clinical Glomerulonephritis 2

14 Apr 2024 5:45 p.m. 6:45 p.m.

SUN-033 to SUN-059

Vanina Vazquez Poster Moderator

Time	Session

5:45 p.m. 6:45 p.m.	THE CHRONICITY INDEX FOR LN BIOPSIES SHOULD BE MODIFIED TO EXCLUDE FIBROUS CRESCENTS? WCN24-AB-2425, Poster Board= SUN-033 SUN-033 Valeria Alberton Poster Presenter	NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL WCN24-AB-1777, Poster Board= SUN-034 SUN-034 Jonathan Barratt Poster Presenter	EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY WCN24-AB-1197, Poster Board= SUN-035 SUN-035 Jonathan Barratt Poster Presenter	NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL WCN24-AB-1776, Poster Board= SUN-036 SUN-036 Jonathan Barratt Poster Presenter	NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2-YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL WCN24-AB-1674, Poster Board= SUN-037 SUN-037 Jonathan Barratt Poster Presenter	ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY WCN24-AB-1294, Poster Board= SUN-038 SUN-038 Jonathan Barratt Poster Presenter	Combined Activity, Recovery, and Chronicity Kidney Biopsy Grading for Prognostic Assessment in ANCA-associated Vasculitis with Glomerulonephritis (AAV-GN) WCN24-AB-390, Poster Board= SUN-039 SUN-039 Marta Casal Moura Poster Presenter	NEUROPSYCHIATRIC SLE (NPSLE) IN CHILDREN AND ADOLESCENTS WITH LUPUS NEPHRITIS WCN24-AB-757, Poster Board= SUN-040 SUN-040 Eugene Yu Hin Chan Poster Presenter	EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS WCN24-AB-2238, Poster Board= SUN-041 SUN-041 Hong Cheng Poster Presenter	SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL WCN24-AB-773, Poster Board= SUN-042 SUN-042 Chee Kay Cheung Poster Presenter	A novel approach to induce early remission in high-risk primary membranous nephropathy WCN24-AB-2290, Poster Board= SUN-043 SUN-043 Vladimir Dobronravov Poster Presenter	ANGIOTENSIN II PROMOTES PODOCYTE APOPTOSIS THROUGH THE MODULATION OF CD2AP AND AMPK WCN24-AB-1679, Poster Board= SUN-044 SUN-044 Tae Sun Ha Poster Presenter	SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY WCN24-AB-846, Poster Board= SUN-045 SUN-045 Bruce Hendry Poster Presenter	EVALUATION OF CD68 AS A MARKER OF ACTIVITY IN LUPUS GLOMERULONEPHRITIS, (IMMUNOHISTOCHEMICAL STUDY) WCN24-AB-2578, Poster Board= SUN-046 SUN-046 Wesam Ismail Poster Presenter	THE GENETIC LANDSCAPE OF ALPORT SYNDROME IN INDIAN PATIENTS WITH PHENOTYPIC CORRELATION WCN24-AB-2438, Poster Board= SUN-047 SUN-047 Trishla Jadon Poster Presenter	PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES WCN24-AB-774, Poster Board= SUN-048 SUN-048 Radko Komers Poster Presenter	CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE) WCN24-AB-752, Poster Board= SUN-049 SUN-049 Radko Komers Poster Presenter	eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL WCN24-AB-1774, Poster Board= SUN-050 SUN-050 Richard Lafayette Poster Presenter	ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I WCN24-AB-1868, Poster Board= SUN-051 SUN-051 Irene Noronha Poster Presenter	ELEVATED MBL LEVELS AND ITS ASSOCIATION WITH ENDOTHELIAL DYSFUNCTION IN PMN WCN24-AB-1513, Poster Board= SUN-052 SUN-052	EFFICACY OF 12-WEEK PEGCETACOPLAN IN KIDNEY TRANSPLANT RECIPIENTS WITH RECURRENT C3 GLOMERULOPATHY (C3G) OR IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) WCN24-AB-683, Poster Board= SUN-053 SUN-053 Lucia Quintana-Gallardo Poster Presenter	TREATMENT PATTERNS IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY - EVIDENCE FROM REAL-WORLD DATA WCN24-AB-1159, Poster Board= SUN-054 SUN-054 Serge Smeets Poster Presenter	REAL-WORLD ANALYSIS OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY WCN24-AB-1158, Poster Board= SUN-055 SUN-055 Serge Smeets Poster Presenter	TREATMENT GOALS FROM THE PERSPECTIVE OF IMMUNOGLOBULIN A NEPHROPATHY PATIENTS - RESULTS FROM A REAL-WORLD STUDY WCN24-AB-1163, Poster Board= SUN-056 SUN-056 Aneesh Thomas George Poster Presenter	POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS WCN24-AB-756, Poster Board= SUN-057 SUN-057 James Tumlin Poster Presenter	EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY WCN24-AB-1001, Poster Board= SUN-058 SUN-058 Muh Geot Wong Poster Presenter	MACHINE-LEARNING ASSISTED DISCOVERY UNVEILS NOVEL INTERPLAY BETWEEN GUT MICROBIOTA AND BRANCHED-CHAIN AMINO ACIDS METABOLISM IN DIABETIC KIDNEY DISEASE WCN24-AB-833, Poster Board= SUN-059 SUN-059 I-Wen Wu Poster Presenter